Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Shuifeijibin for prevention of liver injury during antituberculosis treatment
ChiCTR-TRC-12002076Phase 4Completed
- Sponsor
- Nanjing Medical University School of Public Health
- Start
- Apr 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of silibinin in Tuberculosis (TB) (2 arms), sponsored by Nanjing Medical University School of Public Health. Primary endpoints: Incidence of hepatotoxicity, Blood routine and 1 more. Started Apr 2012; status: completed.
02
Drugs
silibinin
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on ChiCTR-TRC-12002076.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TRC-12002076.